Shopping Cart
- Remove All
Your shopping cart is currently empty
LQVTDSGLYRCVIYHPP (LP17) TFA is a TREM-1 (triggering receptor expressed on myeloid cells) inhibitory peptide that significantly reduces ischemic infarction and neuronal damage, with the ability to penetrate the brain to inhibit TREM-1 [1].

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $60 | In Stock | |
| 5 mg | $147 | In Stock | |
| 10 mg | $216 | In Stock |
| Description | LQVTDSGLYRCVIYHPP (LP17) TFA is a TREM-1 (triggering receptor expressed on myeloid cells) inhibitory peptide that significantly reduces ischemic infarction and neuronal damage, with the ability to penetrate the brain to inhibit TREM-1 [1]. |
| In vitro | METHODS: LQVTDSGLYRCVIYHPP (LP17) TFA (1 or 10 μM) was used in microglia to investigate the function of TREM-1 in the microglial OGD model by real-time quantitative PCR. RESULTS: LQVTDSGLYRCVIYHPP (LP17) TFA significantly reduced the mRNA levels of proinflammatory cytokines (NLRP3, IL-1β, IL-18, IL-6, CD16, CD32, and iNOS) and chemokines (MCP-1, CXCL-1, and CXCL-2); microglia incubated with LQVTDSGLYRCVIYHPP (LP17) maximally preserved neuronal viability. [1] |
| In vivo | METHODS: LQVTDSGLYRCVIYHPP (LP17) TFA (1 mg/kg, intranasal) was used to confirm the biological function of TREM-1 in ischemic stroke. RESULTS: LQVTDSGLYRCVIYHPP (LP17) TFA induced a significant decrease in TUNEL-positive cells and FJC-positive neurons. [1] |
| Molecular Weight | 2075.27 |
| Formula | C91H138F3N23O27S |
| Smiles | [H]N[C@H](C(N[C@H](C(N[C@H](C(N[C@]([H])(C(N[C@@H](CC(O)=O)C(N[C@H](C(NCC(N[C@H](C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@H](C(N[C@@H](CS)C(N[C@H](C(N[C@]([H])(C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CC3=CN=CN3)C(N4CCC[C@H]4C(N5CCC[C@H]5C(O)=O)=O)=O)=O)=O)[C@@H](C)CC)=O)C(C)C)=O)=O)CCCNC(N)=N)=O)=O)CC(C)C)=O)=O)CO)=O)=O)[C@H](O)C)=O)C(C)C)=O)CCC(N)=O)=O)CC(C)C.OC(C(F)(F)F)=O |
| Sequence | H-Leu-Gln-Val-Thr-Asp-Ser-Gly-Leu-Tyr-Arg-Cys-Val-Ile-Tyr-His-Pro-Pro-OH |
| Sequence Short | LQVTDSGLYRCVIYHPP |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | H2O: < 1 mg/mL (insoluble) DMSO: 80 mg/mL (38.55 mM), Sonication is recommended. | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (1.59 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.